Paul Zarogoulidis1,2, Dimitris Petridis3, Haidong Huang4, Chong Bai4, Wolfgang Hohenforst-Schmidt5, Lutz Freitag6, Sofia Baka7, Dimitris Drougas8, Anastasios Vagionas9, Kosmas Tsakiridis10, J Francis Turner11, Dimitris Hatzibougias12, Ioannis Boukovinas13, Bojan Zaric14, Tomi Kovacevic14, Aris Ioannidis15, Nikolaos Courcoutsakis16, Dimitris Matthaios17, Chrisanthi Sardeli18. 1. 3rd Department of Surgery, ``ahepa`` University Hospital, Aristotle University of Thessaloniki, Medical School, Thessaloniki, Greece. 2. Pulmonary Oncology Department, ``Bioclinic`` Private Hospital, Thessaloniki, Greece. 3. Department of Food Technology, School of Food Technology and Nutrition, Alexander Technological Educational Institute, Thessaloniki, Greece. 4. Department of Respiratory & Critical Care Medicine, Changhai Hospital, the Second Military Medical University, Shanghai, China. 5. Sana Clinic Group Franken, Department of Cardiology/Pulmonology/Intensive Care/Nephrology, "Hof" Clinics, University of Erlangen, Hof, Germany. 6. Department of Pulmonology, University Hospital Zurich, Zurich, Switzerland. 7. Oncology Department, ``Interbalkan`` European Medical Center, Thessaloniki, Greece. 8. Nuclear Medicine Department, ``Bioiatriki`` Private PET-CT Laboratory, Thessaloniki, Greece. 9. Oncology Department, General Hospital of Kavala, Kavala, Greece. 10. Thoracic Oncology Department, ``Interbalkan`` European Medical Center, Thessaloniki, Greece. 11. Department of Medicine, University of Tennessee Graduate School of Medicine, Knoxville, USA. 12. Pulmonary department, Private Pathology Laboratory, "Microdiagnostics", Thessaloniki, Greece. 13. Oncology Department, ``Bioclinic`` Private Hospital, Thessaloniki, Greece. 14. Faculty of Medicine, University of Novi Sad, Institute for Pulmonary Diseases of Vojvodina, Novi Sad, Serbia. 15. Surgery Department, ``genesis`` Private HJospital, Thessaloniki, Greece. 16. Radiology Department, Democritus University of Thrace, University General Hospital of Alexandroupolis, Alexandroupolis, Greece. 17. Oncology Department, General Hospital of Rhodes, Thessaloniki, Greece. 18. Department of Pharmacology & Clinical Pharmacology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Abstract
INTRODUCTION: Lung cancer is diagnosed at a late stage due to lack of early disease symptoms. Therefore an efficient treatment is necessary for prolonged disease free survival. PATIENTS AND METHODS: In our study we recruited 124 patients NSCLC patients with adenocarcinoma and squamus cell carcinoma. All recuited patients had Programmed death-ligand 1 expression ≥50 (PD-L1)with DAKO technique. Immunotherapy was administered with as first line treatment. Re-biopsies were performed in the main lung lesion every 4 months with the restaging of the patient and also in the metastastic sites in other organs that occurred during treatment. PD-L1 expressed was evaluated in the biopsies of the metastatic sites. RESULTS: It appears thereafter that the PD-L1 expression could easily be claimed as a promising bio-index with a cutoff value 65, below which a negative prognosis of the disease progress will be evident and above that value a positive continuation of the disease will be prominent. CONCLUSION: The findings of this study suggest that the PD-L1-65 index works adequately either concerning the neo-metastatic sites or the patient disease responses. Re-biopsies in new metastastic sites are necessary since we probably have a new cancer and chemotherapy should be added. More studies should confirm are results and change the NSCLC treatment approach of these patients.
INTRODUCTION: Lung cancer is diagnosed at a late stage due to lack of early disease symptoms. Therefore an efficient treatment is necessary for prolonged disease free survival. PATIENTS AND METHODS: In our study we recruited 124 patients NSCLC patients with adenocarcinoma and squamus cell carcinoma. All recuited patients had Programmed death-ligand 1 expression ≥50 (PD-L1)with DAKO technique. Immunotherapy was administered with as first line treatment. Re-biopsies were performed in the main lung lesion every 4 months with the restaging of the patient and also in the metastastic sites in other organs that occurred during treatment. PD-L1 expressed was evaluated in the biopsies of the metastatic sites. RESULTS: It appears thereafter that the PD-L1 expression could easily be claimed as a promising bio-index with a cutoff value 65, below which a negative prognosis of the disease progress will be evident and above that value a positive continuation of the disease will be prominent. CONCLUSION: The findings of this study suggest that the PD-L1-65 index works adequately either concerning the neo-metastatic sites or the patient disease responses. Re-biopsies in new metastastic sites are necessary since we probably have a new cancer and chemotherapy should be added. More studies should confirm are results and change the NSCLC treatment approach of these patients.
Authors: Paul Zarogoulidis; Christoforos Kosmidis; Eleni-Isidora Perdikouri; Wolfgang Hohemforst-Schmidt; Chrisanthi Sardeli Journal: Respir Med Case Rep Date: 2022-09-15